PF-04929113 (SNX-5422) 908115-27-5

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

521.53 PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.


Biological Activity


PF-04929113 is a small-molecule Hsp90 inhibitor based on the
6,7-dihydro-indazol-4-one scaffold. PF-04929113 developed by Serenex,
converts to SNX-2122, which is the active Hsp90 inhibitor form.
PF-04929113 exhibits potent effects on Her-2 stability and causes
expected up-regulation of Hsp70. PF-04929113 shows potent
antiproliferative activity against a broad range of cancer cell types,
e.g. MCF-7 (IC50=16 nM), SW620 (IC50=19 nM), K562 (IC50=23 nM), SK-MEL-5
(IC50=25 nM), and A375 (IC50=51 nM).


PF-04929113 inhibits human MM cell growth in vivo, and
immuno-histochemical analysis shows PF-04929113 significantly inhibits
p-ERK and p-Akt in treated mice. Meanwhile, PF-04929113 treatment
significantly decreases the percentage of CD31+ cells and MVD,
consistent with an inhibitory effect on Angiogenesis in vivo. A 50 mg/kg
administration of PF-04929113 delivered 3 times per week significantly
delays castrate-resistant LNCaP tumor growth and prolongs cancer
specific survival. Immuno-histochemical analysis indicates increased
SP70 expression, and decreases Ki67, Akt, and AR expression, after
treatment with PF-04929113. Inhibition of tumor progression by
PF-04929113 may result from a combination of decreased proliferative
(reduced Ki67 and Akt expression) or increased Apoptosis (increased
ApopTag staining) rates.


Protocol(Only for Reference)


Kinase Assay: [1]

Affinity for Hsp90

Hsp90 from porcine spleen extract is isolated by affinity capture on a purine-affinity media. The Hsp90 loaded media is then challenged with PF-04929113 at a given concentration, ranging from 0.8 to 500 μM, and the amount of Hsp90 liberated at each concentration is determined by Bradford protein assay. The resulting IC50 values are corrected for the ATP ligand concentration and presented as apparent Kd values.

Cell Assay: [1]

Cell lines	MCF-7, SW620, K562, SK-MEL-5 and A375 cancer cell lines
Concentrations	0-300 nM
Incubation Time	72 or 144 hours
Method	All assays are done in 96-well plates. All cell lines are purchased from ATCC. Proliferation rates are measured by seeding cells into 96-well plates, followed by compound addition 24 h later. After addition of PF-04929113, cells are allowed to grow for either an additional 72 or 144 h depending on rate of growth. At harvest, media is removed and DNA content for individual wells is determined using CyQuant DNA dye. Levels of Hsp90 client Proteins and phosphor-regulated proteins in A375 are measured by high content analysis (HCA) using an ArrayScan 4.5 instrument after 24 hours of treatment with PF-04929113, followed by methanol fixation. After fixation in 4% PBS-buffered formalin and permeablization with 0.1% TX-100, cells are probed with anti-Her2, antiphospho-S6 (pS6), antipERK, and anti-Hsp70 primary antibodies, followed by TRITC or FITC conjugated secondary antibodies. Nuclei are also stained with Hoechst DNA binding dye. For each well, 250-500 individual nuclei are identified along with the average staining intensity for the client and phospho-proteins for each cell. Average client staining intensities are then calculated for each well.

Animal Study: [2]

Animal Models	5 × 106 MM.1S cells are inoculated subcutaneously in the Fox Chase SCID mice (6-7 weeks old).
Formulation	PF-04929113 is dissolved in 1% carboxy methylcellulose/0.5% Tween 80 at 10 mg/mL and stored at 4 °C for in vivo stud
Dosages	20 or 40 mg/kg
Administration	PF-04929113 is administered orally 3 times per week, total 3 weeks.
Solubility	0.5% CMC/0.25% Tween 80, 25 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

Species	Baboon	Dog	Monkey	Rabbit	Guinea pig	Rat	Hamster	Mouse
Weight (kg)	12	10	3	1.8	0.4	0.15	0.08	0.02
Body Surface Area (m2)	0.6	0.5	0.24	0.15	0.05	0.025	0.02	0.007
Km factor	20	20	12	12	8	6	5	3

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B Km
	Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×	mouse Km(3)	= 11.2 mg/kg
	rat Km(6)

Chemical Information

Molecular Weight (MW)	521.53
Formula	C25H30F3N5O4
CAS No.	908115-27-5

Storage	3 years -20℃Powder
	6 months-80℃in solvent (DMSO, water, etc.)
Synonyms

Solubility (25°C) *	In vitro	DMSO	104 mg/mL (199.41 mM)
		Water	<1 mg/mL (
		Ethanol	5 mg/mL (9.58 mM)
	In vivo	0.5% CMC/0.25% Tween 80	25 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Name	(1r,4r)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2-aminoacetate

Molarity Calculator
Dilution Calculator
Molecular Weight Calculator

Contact us if you need more details on 908115-27-5. We are ready to answer your questions on packaging, logistics, certification or any other aspects about PF-04929113 908115-27-5、SNX-5422 908115-27-5. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Cytoskeletal Signaling > HSP Inhibitor